At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03320 CHINARES PHARMA
Market Closed 04-02 16:08:21
6.270
+0.120
+1.95%
High6.280Low6.050Vol44.50M
Open6.150D1 Closing6.150Amplitude3.74%
Mkt Cap39.39BTradable Cap39.39BTotal Shares6.28B
T/O275.99MT/O Rate0.71%Tradable Shares6.28B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
DIARY-China corporate earnings week ahead
Reuters  ·  04-03 12:00
DIARY-China corporate earnings week ahead
CHINARES PHARMA Keeps Share Base Unchanged at 6.28 Billion in March 2026, Confirms Public Float Compliance
Bulletin Express  ·  04-01 17:28
CHINARES PHARMA Keeps Share Base Unchanged at 6.28 Billion in March 2026, Confirms Public Float Compliance
A Look At China Resources Pharmaceutical Group (SEHK:3320) Valuation After 2025 Results And Higher Dividend Proposal
Simply Wall St.  ·  03-30
A Look At China Resources Pharmaceutical Group (SEHK:3320) Valuation After 2025 Results And Higher Dividend Proposal
CHINARES PHARMA Subsidiary CR Pharmaceutical Commercial Completes RMB1.80 Billion First-Tranche 2026 Bond Issue at 1.70% Coupon
Bulletin Express  ·  03-27
CHINARES PHARMA Subsidiary CR Pharmaceutical Commercial Completes RMB1.80 Billion First-Tranche 2026 Bond Issue at 1.70% Coupon
CHINARES PHARMA Subsidiary Successfully Issues 1.8 Billion Yuan Corporate Bonds
Stock News  ·  03-27
CHINARES PHARMA Subsidiary Successfully Issues 1.8 Billion Yuan Corporate Bonds
China Resources Pharmaceutical affiliate CR Pharmaceutical Commercial issues 2026 corporate bonds; RMB1.8 billion tranche sets 1.70% coupon
Reuters  ·  03-27
China Resources Pharmaceutical affiliate CR Pharmaceutical Commercial issues 2026 corporate bonds; RMB1.8 billion tranche sets 1.70% coupon
CLSA Maintains Outperform Rating on China Resources Pharmaceutical, Raises Target Price to HK$7.2
Stock News  ·  03-27
CLSA Maintains Outperform Rating on China Resources Pharmaceutical, Raises Target Price to HK$7.2
CMSC International Raises CHINARES PHARMA (03320) Target Price to HK$6.3, Keeps "Add" Rating
Stock News  ·  03-27
CMSC International Raises CHINARES PHARMA (03320) Target Price to HK$6.3, Keeps "Add" Rating
Stock Track | CHINARES PHARMA Soars 5.25% Intraday on Strong Earnings Results and Positive Outlook
Stock Track  ·  03-27
Stock Track | CHINARES PHARMA Soars 5.25% Intraday on Strong Earnings Results and Positive Outlook
CHINARES PHARMA Shares Extend Rally with Another 5% Gain
Stock News  ·  03-27
CHINARES PHARMA Shares Extend Rally with Another 5% Gain
CHINARES PHARMA Subsidiary Double-Crane Issues Up to RMB 1 Billion Corporate Bonds
Stock News  ·  03-26
CHINARES PHARMA Subsidiary Double-Crane Issues Up to RMB 1 Billion Corporate Bonds
CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon
Bulletin Express  ·  03-26
CR Pharma’s Subsidiary CR Double-Crane Issues RMB1.00 Billion Three-Year Bonds at 1.65% Coupon
CR Double-Crane issues 2026 corporate bonds; principal totals up to RMB1 billion at 1.65% coupon rate
Reuters  ·  03-26
CR Double-Crane issues 2026 corporate bonds; principal totals up to RMB1 billion at 1.65% coupon rate
UBS Adjusts CHINARES PHARMA Target Price to HK$6.9, Citing In-Line Revenue and Above-Expectation Net Profit
Stock News  ·  03-26
UBS Adjusts CHINARES PHARMA Target Price to HK$6.9, Citing In-Line Revenue and Above-Expectation Net Profit
Stock Track | CHINARES PHARMA Soars 6.24% in Morning Session on Strong Annual Results with 20.73% Profit Jump
Stock Track  ·  03-26
Stock Track | CHINARES PHARMA Soars 6.24% in Morning Session on Strong Annual Results with 20.73% Profit Jump
CHINARES PHARMA Shares Surge Over 6% in Morning Trading Following 20.73% Jump in Annual Net Profit
Deep News  ·  03-26
CHINARES PHARMA Shares Surge Over 6% in Morning Trading Following 20.73% Jump in Annual Net Profit
BUZZ-China Resources Pharma hits more than 4-month peak on higher FY profit, dividend
Reuters  ·  03-25
BUZZ-China Resources Pharma hits more than 4-month peak on higher FY profit, dividend
Stock Track | CHINARES PHARMA Soars 5.17% Intraday on Strong FY2025 Results That Beat Estimates
Stock Track  ·  03-25
Stock Track | CHINARES PHARMA Soars 5.17% Intraday on Strong FY2025 Results That Beat Estimates
CHINARES PHARMA Reports Fiscal Year Profit Increase of 20.73% to 4.045 Billion Yuan
Stock News  ·  03-25
CHINARES PHARMA Reports Fiscal Year Profit Increase of 20.73% to 4.045 Billion Yuan
China Resources Pharma proposes final dividend of RMB 0.122 per share
Reuters  ·  03-25
China Resources Pharma proposes final dividend of RMB 0.122 per share
No data available

Introduction

Company Name.
CHINARES PHARMA
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
China Resources Pharmaceutical Group Ltd is an investment holding company principally engaged in the pharmaceutical business. The Company operates its business through four segments. The Pharmaceutical Business segment develops, manufactures and sells a range of pharmaceuticals and health products. The Pharmaceutical Distribution Business segment provides distribution, warehousing, logistics and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers, device manufacturer and dispensers, including hospitals, distributors and retail pharmacies. The Pharmaceutical Retail Business segment operates retail pharmacies. The Other Business Operations segment engages in property holding and other businesses.
Issue price:
--